

# Shashikant Srivastava

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6600344/publications.pdf>

Version: 2024-02-01

96  
papers

3,075  
citations

136950

32  
h-index

189892

50  
g-index

98  
all docs

98  
docs citations

98  
times ranked

2470  
citing authors

#	ARTICLE	IF	CITATIONS
1	An overview of drugs for the treatment of Mycobacterium kansasii pulmonary disease. Journal of Global Antimicrobial Resistance, 2022, 28, 71-77.	2.2	1
2	Rifampin Pharmacokinetics/Pharmacodynamics in the Hollow-Fiber Model of Mycobacterium kansasii Infection. Antimicrobial Agents and Chemotherapy, 2022, 66, e0232021.	3.2	3
3	Mycobacterium tuberculosis sterilizing activity of faropenem, pyrazinamide and linezolid combination and failure to shorten the therapy duration. International Journal of Infectious Diseases, 2021, 104, 680-684.	3.3	7
4	Therapeutic Drug Monitoring in Non-Tuberculosis Mycobacteria Infections. Clinical Pharmacokinetics, 2021, 60, 711-725.	3.5	23
5	Potency of vancomycin against Mycobacterium tuberculosis in the hollow fiber system model. Journal of Global Antimicrobial Resistance, 2021, 24, 403-410.	2.2	7
6	Novel Short-Course Therapy and Morphism Mapping for Clinical Pulmonary Mycobacterium kansasii. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	6
7	Therapeutic drug monitoring and fluoroquinolones for multidrug-resistant tuberculosis. European Respiratory Journal, 2021, 57, 2004454.	6.7	0
8	Comparison of Rifamycins for Efficacy Against Mycobacterium avium Complex and Resistance Emergence in the Hollow Fiber Model System. Frontiers in Pharmacology, 2021, 12, 645264.	3.5	9
9	Cefdinir and $\beta$ -Lactamase Inhibitor Independent Efficacy Against Mycobacterium tuberculosis. Frontiers in Pharmacology, 2021, 12, 677005.	3.5	12
10	Repurposing Cefazolin-Avibactam for the Treatment of Drug Resistant Mycobacterium tuberculosis. Frontiers in Pharmacology, 2021, 12, 776969.	3.5	5
11	Duration of pretomanid/moxifloxacin/pyrazinamide therapy compared with standard therapy based on time-to-extinction mathematics. Journal of Antimicrobial Chemotherapy, 2020, 75, 392-399.	3.0	14
12	A Human Lung Challenge Model to Evaluate the Safety and Immunogenicity of PPD and Live Bacillus Calmette-Guérin. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1277-1291.	5.6	28
13	Comparison of a Novel Regimen of Rifapentine, Tedizolid, and Minocycline with Standard Regimens for Treatment of Pulmonary Mycobacterium kansasii. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	8
14	sncRNA-1 Is a Small Noncoding RNA Produced by Mycobacterium tuberculosis in Infected Cells That Positively Regulates Genes Coupled to Oleic Acid Biosynthesis. Frontiers in Microbiology, 2020, 11, 1631.	3.5	3
15	Redox Imbalance and Oxidative DNA Damage During Isoniazid Treatment of HIV-Associated Tuberculosis: A Clinical and Translational Pharmacokinetic Study. Frontiers in Pharmacology, 2020, 11, 1103.	3.5	1
16	Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2020, 65, .	3.2	13
17	Evaluation of Ceftriaxone Plus Avibactam in an Intracellular Hollow Fiber Model of Tuberculosis: Implications for the Treatment of Disseminated and Meningeal Tuberculosis in Children. Pediatric Infectious Disease Journal, 2020, 39, 1092-1100.	2.0	10
18	Optimal Dose or Optimal Exposure? Consideration for Linezolid in Tuberculosis Treatment. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	2

#	ARTICLE	IF	CITATIONS
19	Dynamic imaging in patients with tuberculosis reveals heterogeneous drug exposures in pulmonary lesions. <i>Nature Medicine</i> , 2020, 26, 529-534.	30.7	87
20	Repurposing drugs for treatment of <i>Mycobacterium abscessus</i> : a view to a kill. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1212-1217.	3.0	36
21	Effect of specimen processing, growth supplement, and different metabolic population on <i>Mycobacterium tuberculosis</i> laboratory diagnosis. <i>PLoS ONE</i> , 2020, 15, e0230927.	2.5	10
22	Tedizolid, Faropenem, and Moxifloxacin Combination With Potential Activity Against Nonreplicating <i>Mycobacterium tuberculosis</i> . <i>Frontiers in Pharmacology</i> , 2020, 11, 616294.	3.5	8
23	Optimizing ethambutol dosing among HIV/tuberculosis co-infected patients: a population pharmacokinetic modelling and simulation study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2994-3002.	3.0	6
24	Spatial Network Mapping of Pulmonary Multidrug-Resistant Tuberculosis Cavities Using RNA Sequencing. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 370-380.	5.6	27
25	Once-a-week tigecycline for the treatment of drug-resistant TB. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1607-1617.	3.0	13
26	Development of an animal model of <i>Helicobacter pylori</i> (Indian strain) infection. <i>Indian Journal of Gastroenterology</i> , 2019, 38, 167-172.	1.4	1
27	Minocycline Immunomodulates via Sonic Hedgehog Signaling and Apoptosis and Has Direct Potency Against Drug-Resistant Tuberculosis. <i>Journal of Infectious Diseases</i> , 2019, 219, 975-985.	4.0	18
28	Reply to Zimenkov, "Mutation in luxR Family Transcriptional Regulator Rv0890c Is Not a Marker of Linezolid Resistance". <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	0
29	Urine colorimetry for therapeutic drug monitoring of pyrazinamide during tuberculosis treatment. <i>International Journal of Infectious Diseases</i> , 2018, 68, 18-23.	3.3	15
30	Transformation Morphisms and Time-to-Extinction Analysis That Map Therapy Duration From Preclinical Models to Patients With Tuberculosis: Translating From Apples to Oranges. <i>Clinical Infectious Diseases</i> , 2018, 67, S349-S358.	5.8	26
31	Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis. <i>Clinical Infectious Diseases</i> , 2018, 67, S274-S283.	5.8	23
32	Multiparameter Responses to Tedizolid Monotherapy and Moxifloxacin Combination Therapy Models of Children With Intracellular Tuberculosis. <i>Clinical Infectious Diseases</i> , 2018, 67, S342-S348.	5.8	18
33	Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis. <i>Clinical Infectious Diseases</i> , 2018, 67, S293-S302.	5.8	74
34	Linezolid-based Regimens for Multidrug-resistant Tuberculosis (TB): A Systematic Review to Establish or Revise the Current Recommended Dose for TB Treatment. <i>Clinical Infectious Diseases</i> , 2018, 67, S327-S335.	5.8	53
35	Efficacy Versus Hepatotoxicity of High-dose Rifampin, Pyrazinamide, and Moxifloxacin to Shorten Tuberculosis Therapy Duration: There Is Still Fight in the Old Warriors Yet!. <i>Clinical Infectious Diseases</i> , 2018, 67, S359-S364.	5.8	17
36	Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis. <i>Clinical Infectious Diseases</i> , 2018, 67, S317-S326.	5.8	29

#	ARTICLE	IF	CITATIONS
37	The Sterilizing Effect of Intermittent Tedizolid for Pulmonary Tuberculosis. <i>Clinical Infectious Diseases</i> , 2018, 67, S336-S341.	5.8	26
38	Clofazimine for the Treatment of <i>Mycobacterium kansasii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	15
39	Drug-Penetration Gradients Associated with Acquired Drug Resistance in Patients with Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 1208-1219.	5.6	130
40	Antibacterial and Sterilizing Effect of Benzylpenicillin in Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	29
41	Markers of gut dysfunction do not explain low rifampicin bioavailability in HIV-associated TB. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2020-2027.	3.0	6
42	pH Conditions under Which Pyrazinamide Works in Humans. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	5
43	Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis. <i>Science Advances</i> , 2017, 3, e1701102.	10.3	56
44	Systematic Review and Meta-analyses of the Effect of Chemotherapy on Pulmonary <i>Mycobacterium abscessus</i> Outcomes and Disease Recurrence. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	99
45	Sterilizing Effect of Ertapenem-Clavulanate in a Hollow-Fiber Model of Tuberculosis and Implications on Clinical Dosing. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	23
46	Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activation. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 801-811.	2.4	19
47	The discovery of ceftazidime/avibactam as an anti- <i>Mycobacterium avium</i> agent. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, i36-i42.	3.0	29
48	Meta-analyses and the evidence base for microbial outcomes in the treatment of pulmonary <i>Mycobacterium avium</i> –intracellular complex disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, i13-i19.	3.0	51
49	Linezolid as treatment for pulmonary <i>Mycobacterium avium</i> disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, i24-i29.	3.0	25
50	Tedizolid is highly bactericidal in the treatment of pulmonary <i>Mycobacterium avium</i> complex disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, i30-i35.	3.0	34
51	A novel ceftazidime/avibactam, rifabutin, tedizolid and moxifloxacin (CARTM) regimen for pulmonary <i>Mycobacterium avium</i> disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, i48-i53.	3.0	25
52	A “shock and awe” thioridazine and moxifloxacin combination-based regimen for pulmonary <i>Mycobacterium avium</i> –intracellular complex disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, i43-i47.	3.0	14
53	A programme to create short-course chemotherapy for pulmonary <i>Mycobacterium avium</i> disease based on pharmacokinetics/pharmacodynamics and mathematical forecasting. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, i54-i60.	3.0	11
54	Failure of the azithromycin and ethambutol combination regimen in the hollow-fibre system model of pulmonary <i>Mycobacterium avium</i> infection is due to acquired resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, i20-i23.	3.0	11

#	ARTICLE	IF	CITATIONS
55	Linezolid Dose That Maximizes Sterilizing Effect While Minimizing Toxicity and Resistance Emergence for Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	81
56	Pyrazinamide clearance is impaired among HIV/tuberculosis patients with high levels of systemic immune activation. <i>PLoS ONE</i> , 2017, 12, e0187624.	2.5	12
57	Tigecycline Is Highly Efficacious against Mycobacterium abscessus Pulmonary Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2895-2900.	3.2	54
58	Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3779-3785.	3.2	25
59	Susceptibility Testing of Antibiotics That Degrade Faster than the Doubling Time of Slow-Growing Mycobacteria: Ertapenem Sterilizing Effect versus Mycobacterium tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3193-3195.	3.2	23
60	Failure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Treating Pulmonary Mycobacterium abscessus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6374-6376.	3.2	41
61	Artificial Intelligence and Amikacin Exposures Predictive of Outcomes in Multidrug-Resistant Tuberculosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5928-5932.	3.2	37
62	Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo. <i>Clinical Infectious Diseases</i> , 2016, 63, S88-S94.	5.8	37
63	A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way. <i>Clinical Infectious Diseases</i> , 2016, 63, S95-S101.	5.8	40
64	Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks. <i>Clinical Infectious Diseases</i> , 2016, 63, S102-S109.	5.8	34
65	Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests. <i>Clinical Infectious Diseases</i> , 2016, 63, S63-S74.	5.8	102
66	A Combination Regimen Design Program Based on Pharmacodynamic Target Setting for Childhood Tuberculosis: Design Rules for the Playground. <i>Clinical Infectious Diseases</i> , 2016, 63, S75-S79.	5.8	13
67	Linezolid for Infants and Toddlers With Disseminated Tuberculosis: First Steps. <i>Clinical Infectious Diseases</i> , 2016, 63, S80-S87.	5.8	39
68	Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5922-5927.	3.2	31
69	Thioridazine as Chemotherapy for Mycobacterium avium Complex Diseases. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4652-4658.	3.2	27
70	A Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in Babies. <i>EBioMedicine</i> , 2016, 6, 126-138.	6.1	40
71	Amikacin Pharmacokinetics/Pharmacodynamics in a Novel Hollow-Fiber Mycobacterium abscessus Disease Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1242-1248.	3.2	41
72	Rapid Drug Tolerance and Dramatic Sterilizing Effect of Moxifloxacin Monotherapy in a Novel Hollow-Fiber Model of Intracellular Mycobacterium kansasii Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2273-2279.	3.2	21

#	ARTICLE	IF	CITATIONS
73	Fatal Lure of Look-Back Studies in Explaining Pharmacological Events Such as Acquired Drug Resistance in Patients With Multidrug-Resistant Tuberculosis. <i>Journal of Infectious Diseases</i> , 2015, 212, 166-167.	4.0	2
74	Comment on: Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 320-321.	3.0	5
75	Minimum inhibitory concentration, pharmacokinetics/pharmacodynamics and therapeutic drug monitoring: An integrated approach for multidrug-resistant tuberculosis. <i>Lung India</i> , 2015, 32, 402-3.	0.7	0
76	Integrating drug concentrations and minimum inhibitory concentrations with Bayesian-dose optimisation for multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2014, 43, 312-313.	6.7	7
77	Acquired Drug Resistance Because of Pharmacokinetic Variability in a Young Child With Tuberculosis. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 1205.	2.0	7
78	<i>In vitro</i> susceptibility testing and totally drug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2013, 42, 291-292.	6.7	3
79	Thioridazine Pharmacokinetic-Pharmacodynamic Parameters "Wobble" during Treatment of Tuberculosis: a Theoretical Basis for Shorter-Duration Curative Monotherapy with Congeners. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5870-5877.	3.2	42
80	Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment?. <i>European Respiratory Journal</i> , 2013, 42, 1449-1453.	6.7	46
81	New Susceptibility Breakpoints and the Regional Variability of MIC Distribution in Mycobacterium tuberculosis Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5428-5428.	3.2	19
82	Mycobacterial Shuttle Vectors Designed for High-Level Protein Expression in Infected Macrophages. <i>Applied and Environmental Microbiology</i> , 2012, 78, 6829-6837.	3.1	12
83	Scientific and patient care evidence to change susceptibility breakpoints for first-line anti-tuberculosis drugs [Correspondence]. <i>International Journal of Tuberculosis and Lung Disease</i> , 2012, 16, 706-707.	1.2	4
84	Reply to "Pharmacokinetic Mismatch of Tuberculosis Drugs". <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1667-1667.	3.2	0
85	The Antibiotic Resistance Arrow of Time: Efflux Pump Induction Is a General First Step in the Evolution of Mycobacterial Drug Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4806-4815.	3.2	158
86	Meta-Analysis of Clinical Studies Supports the Pharmacokinetic Variability Hypothesis for Acquired Drug Resistance and Failure of Antituberculosis Therapy. <i>Clinical Infectious Diseases</i> , 2012, 55, 169-177.	5.8	199
87	Pharmacokinetic Mismatch Does Not Lead to Emergence of Isoniazid- or Rifampin-Resistant Mycobacterium tuberculosis but to Better Antimicrobial Effect: a New Paradigm for Antituberculosis Drug Scheduling. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5085-5089.	3.2	44
88	Multidrug-Resistant Tuberculosis Not Due to Noncompliance but to Between-Patient Pharmacokinetic Variability. <i>Journal of Infectious Diseases</i> , 2011, 204, 1951-1959.	4.0	246
89	In Vitro and In Vivo Modeling of Tuberculosis Drugs and its Impact on Optimization of Doses and Regimens. <i>Current Pharmaceutical Design</i> , 2011, 17, 2881-2888.	1.9	36
90	Moxifloxacin Pharmacokinetics/Pharmacodynamics and Optimal Dose and Susceptibility Breakpoint Identification for Treatment of Disseminated Mycobacterium avium Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2534-2539.	3.2	46

#	ARTICLE	IF	CITATIONS
91	Effluxâ€Pumpâ€Derived Multiple Drug Resistance to Ethambutol Monotherapy in <i>Mycobacterium tuberculosis</i> and the Pharmacokinetics and Pharmacodynamics of Ethambutol. <i>Journal of Infectious Diseases</i> , 2010, 201, 1225-1231.	4.0	119
92	Ethambutol Optimal Clinical Dose and Susceptibility Breakpoint Identification by Use of a Novel Pharmacokinetic-Pharmacodynamic Model of Disseminated Intracellular <i>Mycobacterium avium</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1728-1733.	3.2	57
93	emb nucleotide polymorphisms and the role of embB306 mutations in <i>Mycobacterium tuberculosis</i> resistance to ethambutol. <i>International Journal of Medical Microbiology</i> , 2009, 299, 269-280.	3.6	26
94	Prevalence of H. influenzae type b & f among unvaccinated patients with respiratory tract infection and meningitis. <i>World Journal of Microbiology and Biotechnology</i> , 2008, 24, 1977-1979.	3.6	1
95	Nucleotide Polymorphism Associated with Ethambutol Resistance in Clinical Isolates of <i>Mycobacterium tuberculosis</i> . <i>Current Microbiology</i> , 2006, 53, 401-405.	2.2	38
96	Antibiotic Susceptibility of <i>Helicobacter pylori</i> Clinical Isolates: Comparative Evaluation of Disk-Diffusion and E-Test Methods. <i>Current Microbiology</i> , 2006, 53, 329-334.	2.2	34